[Credit: National Human Genome Research Institute]
The complexity and diversity of cell and gene therapies and treatments still restrains the industry’s ability to identify and deliver the proper treatment and a positive patient experience. In 2023, I expect we will see a considerable increase in critical data gathering and machine learning analysis that will lead to substantive improvements. This use of machine learning requires a continual commitment to invest in technology as it develops to ensure the required infrastructure is in place to achieve the most significant advances. And, while the infrastructure required to optimize machine learning fully is still in development, we will begin to realize its impact on drug discovery and development and on our ability to deliver personalized medicine this year.Such leaps forward in the cell and gene therapy industry requires a growing emphasis on innovation. And t…